Join
Live feed
·
PRReleasevia Quantisnow
Travere Therapeutics Inc. logo

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

ByQuantisnow·Wall Street's wire, on your screen.
TVTX· Travere Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TVTX (Travere Therapeutics Inc.) and more on Quantisnow.